18:43 , Aug 10, 2018 |  BC Week In Review  |  Company News

India's Glenmark grants China's Harbour rights to bispecific mAb for cancer

Indian company Glenmark Pharmaceuticals Ltd. (NSE:GLENMARK; BSE:532296) granted Harbour BioMed (Shanghai, China) rights to develop and commercialize GBR 1302 in Greater China, including Hong Kong and Macau, and Taiwan. The deal is Glenmark’s first with...
21:48 , Aug 6, 2018 |  BC Extra  |  Company News

India's Glenmark grants China's Harbour rights to bispecific mAb for cancer

Indian company Glenmark Pharmaceuticals Ltd. (NSE:GLENMARK; BSE:532296) granted Harbour BioMed (Shanghai, China) rights to develop and commercialize GBR 1302 in Greater China. According to BioCentury’s BCIQ database, the deal is Glenmark’s first with a Chinese...
00:46 , Aug 4, 2018 |  BioCentury  |  Finance

Functions of formulation

Halozyme Therapeutics Inc. is quickly expanding the reach of its Enhanze platform on the back of regulatory approvals for products that are now gaining market share, plus a playbook for streamlined early development it can...
23:41 , Aug 3, 2018 |  BioCentury  |  Emerging Company Profile

Compass’ range

Compass Therapeutics LLC combines human cell display, high throughput antibody screening and a multispecific engineering platform to develop large libraries of cancer and autoimmune therapies. Traditional approaches to antibody discovery use hybridoma fusions in animals,...
19:13 , Jul 20, 2018 |  BC Week In Review  |  Clinical News

Partial clinical hold on ADC sinks Mersana shares

Mersana Therapeutics Inc. (NASDAQ:MRSN) lost $5.20 (32%) to $11.26 on July 19 after it said FDA placed a partial clinical hold on a Phase I trial of XMT-1522 following a "possibly drug-related" patient death. The...
20:38 , Jul 19, 2018 |  BC Extra  |  Company News

Partial clinical hold on ADC sinks Mersana shares

Mersana Therapeutics Inc. (NASDAQ:MRSN) lost $5.20 (32%) to $11.26 on Thursday after it said FDA placed a partial clinical hold on a Phase I trial of XMT-1522 following a "possibly drug-related" patient death. The event...
20:07 , Jul 13, 2018 |  BC Week In Review  |  Clinical News

EMA's CHMP recommends CAR Ts, rare disease therapies

EMA's CHMP recommended for approval Kymriah tisagenlecleucel and Yescarta axicabtagene ciloleucel, the first two CAR T therapies backed by the committee. CHMP also recommended a handful of other Orphan drug candidates, including Cablivi caplicizumab, a key...
20:20 , Jun 29, 2018 |  BC Extra  |  Company News

CHMP backs CAR Ts, Orphan candidates

EMA's CHMP recommended for approval Kymriah tisagenlecleucel and Yescarta axicabtagene ciloleucel, the first two CAR T therapies backed by the committee. CHMP also recommended a handful of other Orphan drug candidates, including Cablivi caplicizumab, a...
19:48 , Jun 29, 2018 |  BioCentury  |  Finance

Carisma’s attraction

Macrophage immunotherapy play Carisma Therapeutics Inc. has developed biomarkers that it can use to track macrophage activity and tumor response in preclinical and clinical studies, leading Wellington Partners to join its $53 million series A...
14:52 , Jun 29, 2018 |  BC Week In Review  |  Financial News

AbbVie Ventures, HealthCap lead Carisma's $53M series A

Macrophage immunotherapy company Carisma Therapeutics Inc. (Philadelphia, Pa.) raised $53 million in a series A round led by existing investors AbbVie Ventures and HealthCap. Existing investors IP Group plc (LSE:IPO), Penn Medicine and Grazia Equity,...